:: Library Catalog

Buchumschlag

Gespeichert in:

Bibliographische Detailangaben
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	British Journal of Pharmacology
Online-Zugang:	https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70013
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Genetic polymorphisms influencing antihypertensive drug responses
von: Jana El Cheikh, et al.
Veröffentlicht: (2024)

Assessment of the influence of body fat indices on antihypertensive drug responses
von: Duygun Altıntaş Aykan, et al.
Veröffentlicht: (2024)

Advancing antihypertensive drug development
von: Fay Pu, et al.
Veröffentlicht: (2025)

Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first‐line antihypertensive drugs
von: Cristina González‐Correa, et al.
Veröffentlicht: (2024)

Exploring the link between antihypertensive drugs targets and pancreatitis risk through Mendelian randomization
von: Zhiwei Du, et al.
Veröffentlicht: (2025)

RETRACTED: Effects of different antihypertensive drug classes on central and ambulatory blood pressure in resistant hypertension: A randomized clinical trial
von: Juan Carlos Yugar‐Toledo, et al.
Veröffentlicht: (2025)

Evaluation of the antihypertensive and antihyperlipidaemic effects of a pyrimidine derivative in preventing cardiometabolic risk
von: Baskar Aswinanand, et al.
Veröffentlicht: (2026)

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers
von: Andrej Belančić, et al.
Veröffentlicht: (2025)

Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response
von: Magnus Ingelman‐Sundberg, et al.
Veröffentlicht: (2024)

Letter to the editor: Personalized antihypertensive treatment—The role of body fat indices beyond body mass index
von: Christina Antza, et al.
Veröffentlicht: (2024)

Understanding factors that influence the drug choice of prescribers: A Q‐methodology study
von: Mariëlle G. Hartjes, et al.
Veröffentlicht: (2025)

Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations
von: Tahira Foyzun, et al.
Veröffentlicht: (2024)

Opportunities of patient‐derived organoids in drug development
von: Antonia Büning, et al.
Veröffentlicht: (2025)

Chemistry/structural biology of psychedelic drugs and their receptor(s)
von: Ryan H. Gumpper, et al.
Veröffentlicht: (2024)

Emerging therapeutic opportunities for psychedelic and related drugs
von: Susan Wonnacott, et al.
Veröffentlicht: (2026)

The eyes of the beholder: Perceived barriers to successful drug repurposing
von: Zsuzsanna Ida Petykó, et al.
Veröffentlicht: (2025)

Exploring drug mechanisms through single‐cell proteomics
von: Yuzhi Sun, et al.
Veröffentlicht: (2026)

Placebo response and its influencing factors in acne vulgaris: A model‐based meta‐analysis
von: Jieren Luo, et al.
Veröffentlicht: (2026)

Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry
von: Juliana Salazar, et al.
Veröffentlicht: (2024)

Natural products and cancer: From drug discovery to prevention and therapy
von: Angelo A. Izzo, et al.
Veröffentlicht: (2025)

Artificial intelligence streamlines scientific discovery of drug–target interactions
von: Yuxin Yang, et al.
Veröffentlicht: (2025)

Identification of drug repurposing candidates for the treatment of polycystic kidney disease
von: Alina Meyer, et al.
Veröffentlicht: (2026)

Experience of a nirmatrelvir/ritonavir drug–drug interaction expert advice service
Veröffentlicht: (2024)

A case report highlighting drug–drug interactions between 3 life‐saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs
von: Tara Suchak, et al.
Veröffentlicht: (2024)

Effects of routes, concentrations and genetic polymorphisms on posaconazole–tacrolimus interactions in allogeneic haematopoietic cell transplantation
von: Masatomo Kuno, et al.
Veröffentlicht: (2025)

System level network data and models attack cancer drug resistance
von: Márk Kerestély, et al.
Veröffentlicht: (2025)

The use of different types of networks, alone and in combination, for drug target identification
von: Paolo Parini
Veröffentlicht: (2025)

Network medicine and systems pharmacology approaches to predicting adverse drug effects
von: Alessio Funari, et al.
Veröffentlicht: (2024)

Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties
von: Geofrey Oteng Phutietsile, et al.
Veröffentlicht: (2024)

Dreaming of a cardiovascular drug sanctuary: Why some old drugs still matter
von: Lukas Kloesges, et al.
Veröffentlicht: (2026)

A computer‐aided drug repurposing: the antibacterial agents targeting GroEL
von: Dongdong Zhang, et al.
Veröffentlicht: (2025)

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
von: Stavros Topouzis, et al.
Veröffentlicht: (2025)

Bispecific nanobody® as a new pharmacological drug for the selective inhibition of Trypsin‐3
von: Melissa David, et al.
Veröffentlicht: (2025)

Interindividual variability in olanzapine steady‐state concentrations in Chinese: exploring single nucleotide polymorphisms of metabolic enzymes
von: Zhou Wan, et al.
Veröffentlicht: (2025)

Arbidol, an antiviral drug, identified as a sodium channel blocker with anticonvulsant activity
von: Min Li, et al.
Veröffentlicht: (2024)

Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling
Veröffentlicht: (2024)

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption
von: Sarah Alrubia, et al.
Veröffentlicht: (2025)

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach
von: Judith Berres, et al.
Veröffentlicht: (2026)

Novel approaches for drug development against chronic primary pain: A systematic review
von: Valéria Tékus, et al.
Veröffentlicht: (2025)

Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients
von: Sherouk M. Okda, et al.
Veröffentlicht: (2024)